About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT03122093

Celiac Disease and Diabetes Longitudinal Follow-up and Evaluation Study

To the investigators' knowledge, no single long-term prospective observational study has assessed dietary factors, diabetes clinical variables (metabolic control and associated complications), and sel...

Lead sponsor: The Hospital for Sick Children•6 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The Hospital for Sick Children

Age

8 - 50 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Males and females between the ages of 8 and 50 years with positive/weakly positive serologic CD screening or who have completed the CD-DIET trial.
•2. Diagnosis of T1D by American Diabetes Association (ADA) criteria with duration of T1D equal to or greater than 1 year from time of signing Screening Informed Consent for CD-DIET trial.
•3. Ability of the subject or a legally authorized representative to speak and read English or French.
•4. Participation in the screening portion of the CD-DIET Study.

Exclusion Criteria

•1\. A condition which, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.

Related studies

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

NCT07362654 · Celiac Disease, Gluten Sensitivity, and more

RECRUITINGPhase 2

Study of DONQ52 in Active Celiac Disease

NCT07239336 · Celiac Disease

Gluten Challenge in Celiac Disease - Which Formulation of Gluten Gives the Best Response?

NCT07039773 · Celiac Disease

RECRUITINGPhase 3

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137 · Diabetes Mellitus, Type 1

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

NCT06807190 · Diabetes Mellitus, Type 1

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 3, 2021Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment90

Start dateMay 2017

Last updatedMar 3, 2021

Condition

Celiac Disease Celiac Diabetes Mellitus, Type 1

Locations shown

McMaster University

Hamilton, Ontario

Kingston General Hospital

Kingston, Ontario

London Health Sciences

London, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions